TET2 and blast phase chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, mutations in IDH1/2 or TET2 are not equally distributed across disease entities in that IDH1/2 are more frequent in blast phase disease whereas TET2 occurs with equal frequency in chronic and blast phase disease [54].